Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort

Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L.E., Lasthein, S., Lindhardsen, J., Kristensen, S.L., Torp‐Pedersen, C., Hansen, P.R.·2015·Journal of the European Academy of Dermatology and Venereology

Abstract

Background: Psoriasis is a common disease and is associated with cardiovascular diseases. Systemic anti‐inflammatory drugs may reduce risk of cardiovascular events. We therefore examined the rate of cardiovascular events, i.e. cardiovascular death, myocardial infarction and stroke, in patients with severe psoriasis treated with systemic anti‐inflammatory drugs. Methods: Individual‐level linkage of administrative registries was used to perform a longitudinal nationwide cohort study. Time‐dependent multivariable adjusted Cox regression was used to estimate hazard ratios (HR s) with 95% confidence intervals (CI s) of cardiovascular events associated with use of biological drugs, methotrexate, cyclosporine, retinoids and other antipsoriatic therapies, including topical treatments, phototherapy and climate therapy. Results: A total of 6902 patients (9662 treatment exposures) with a maximum follow‐up of 5 years were included. Incidence rates per 1000 patients‐years for cardiovascular events were 4.16, 6.28, 6.08, 18.95 and 14.63 for biological drugs, methotrexate, cyclosporine, retinoid and other therapies respectively. Relative to other therapies, methotrexate (HR 0.53; CI 0.34–0.83) was associated with reduced risk of the composite endpoint and a comparable but non‐significant protective effect was observed with biological drugs (HR 0.58; CI 0.30–1.10), whereas no protective effect was apparent with cyclosporine (HR 1.06; CI 0.26–4.27) and retinoids (HR 1.80; CI 1.03–2.96). Tumour necrosis factor inhibitors (HR 0.46; CI 0.22–0.98) were linked to reduced event rates, whereas the interleukin‐12/23 inhibitor ustekinumab (HR 1.52; CI 0.47–4.94) was not. Conclusion: Systemic anti‐inflammatory treatment with methotrexate was associated with significantly lower rates of cardiovascular events during long‐term follow‐up compared to patients treated with other antipsoriatic therapies. The treatment strategy in patients with severe psoriasis may have an impact on cardiovascular outcomes and randomized trials to evaluate the cardiovascular safety and efficacy of systemic antipsoriatic therapies are called for.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdv.12768

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 189

Metadata

Authors
Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L. E., Lasthein, S., Lindhardsen, J., Kristensen, S. L., Torp‐Pedersen, C., & Hansen, P. R.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2014-10-10
Volume
29
Issue
6
Pages
1128-1134
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W1969097286
Cited by
189
References
7
FWCI
7.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort. https://app.cochat.ai/papers/10.1111/jdv.12768
The paper
Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L. E., Lasthein, S., Lindhardsen, J., Kristensen, S. L., Torp‐Pedersen, C., & Hansen, P. R. (2015). Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.12768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.